Which company makes Olaparib?

Olaparib was developed and first used in patients by KuDOS Pharmaceuticals, a British biotechnology company founded by Stephen Jackson of the University of Cambridge in the UK. Since AstraZeneca acquired KuDOS in 2006, AstraZeneca and Merck have conducted clinical development of the drug.

In December 2014, the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approved olaparib as monotherapy. The FDA approves three or more chemotherapy treatments for advanced ovarian cancer with BRCA germline mutations (gBRCAm). The EMA's public assessment report used the same Phase II trial data, but also mentioned the use of olaparib in "high-grade serous ovarian cancer" and "when the tumor size decreases or disappears completely within 8 weeks after a course of platinum therapy." Olaparib is a polyadenosine5'-bisphosphate ribose polymerase (PARP) enzyme inhibitor. It works by killing cancer cells. The common specification preparation is a tablet that can be taken orally twice a day and can be taken with or without food.

Lynparza The original drug has been launched in China and has entered the scope of Class B medical insurance, but it is only available to patients who meet the indications. The price of each box of 150mg*56 tablets may be around RMB 6,000. There are price differences for drugs of different specifications. There are also Olaparibgeneric drugs produced overseas. The specifications produced by Bangladesh pharmaceutical factories150mg*120 tablets per box may cost around RMB 4,000 (the price may fluctuate due to the exchange rate). Its drug ingredients are basically the same as those of the Olaparib original drug. For more drug information and specific prices, please consult Yaode Medical Consultant.